Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Glycemic Control & CV outcome study by lars bryden

187 views

Published on

CV outcome with new class of Drug SGLT2 Inhibitor specially Empagliflozin recently approved by USFDA and EMA for Treatment of long standing Type 2 diabetes with reduction in CVD Mortality,all cause mortlaity and Morbidity(Primary outcome-3 point MACE,time to Ist occurence of CV death,Nonfatal MI or Non fatal stroke and Key secondary outcome 4 point MACE:time to first occurence of MI,nonfatal stroke or hospitalisation for UA.EMPA-REG OUTCOME:further Prespecified Outcome
>CV DEATH
>NONFATAL MI
>NONFATAL STROKE
>HOSPITALISATION FOR HF
>ALL CAUSE MORTALITY

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

×